Vétoquinol S.A., a veterinary pharmaceutical laboratory, designs, develops, and sells veterinary drugs and non-medicinal products serving both the companion animals and livestock, and bred for human food markets in Europe, the Americas, and the Asia Pacific region. It offers pain management, anti-infective, cardiology-nephrology, care and hygiene, antiparasiticides, behavior, internal medicine, and reproduction related products for dogs, cats, cattle, and pigs. The company offers its prdoucts under Tolfedine CS, Tolfine, Cimalgex, Flexadin, Caniviton, Diurizone, Marbocyl, Forcyl, Ceftiocyl, Clavaseptin, Clindaseptin, Cefaseptin, Kefloril, Aurizon, Oridermyl, Longamox, Pen-Histra-Strep, Doxicor, Amoxinsol, Aluspray, Linspec, Permacyl, UpCard, Prilium, Ipakitine/Epakitine, Azodyl, Rubenal, Flevox, Dolpac, Zylkene, and Zentonil brands. The company was founded in 1933 and is headquartered in Lure, France. Vétoquinol S.A. is a subsidiary of Soparfin SCA.
Type
Public
HQ
Lure, FR
Founded
1933
Size (employees)
2,084 (est)+3%
Vetoquinol was founded in 1933 and is headquartered in Lure, FR
Report incorrect company information

Vetoquinol Office Locations

Vetoquinol has an office in Lure
Lure, FR (HQ)
BP 189
Show all (1)
Report incorrect company information

Vetoquinol Financials and Metrics

Vetoquinol Financials

Market capitalization (2-Oct-2017)

656.9 m

Closing share price (2-Oct-2017)

54.4
Vetoquinol's current market capitalization is €656.9 m.
Show all financial metrics
Report incorrect company information